Pfizer’s Big Breakthrough for Breast Cancer

An experimental breast cancer therapy treatment from Pfizer (NYSE:PFE) has been given the Food and Drug Administration’s ‘breakthrough therapy designation.’ This recognition of the new drug could help expedite development on this drug.

This designation was awarded as a result of data that was presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium. At the Symposium, the company presented findings that the women who were treated with a combination of letrozole and palbociclib achieved significant progress compared to the women who took letrozole alone.

NEW! Discover a new stock idea each week for less than the cost of 1 trade. CLICK HERE for your Weekly Stock Cheat Sheets NOW!

Patients who were treated with a combination of drugs “went more than 26 months without worsening symptoms, as opposed to 7.5 months for patients only using letrozole.” The drug will go into testing for Phase III.

More Articles About:   , , , , , , ,